小细胞肺癌脑转移一线立体定向放疗与全脑放疗比较:FIRE-SCLC队列研究
FIRE-SCLC多中心队列研究纳入710例接受一线SRS的小细胞肺癌脑转移患者,中位总生存8.5个月,中位至中枢神经系统进展时间8.1个月。
要点
- 一线SRS治疗小细胞肺癌脑转移的中位总生存为8.5个月。
- SRS的TTCP短于WBRT,但总生存无改善。
- 软脑膜进展和神经性死亡发生率较低。
核心结论
- 一线SRS不联合WBRT的主要权衡是TTCP缩短,但总生存未下降,与SRS已确立地位的其他肿瘤类型相似。
研究设计与样本
- 多中心队列研究,分析28个中心及一项单臂试验的SRS结局,并与一线WBRT队列比较。
- 共纳入710例接受SRS的患者,中位年龄68.5岁,男性531例(74.8%)。
主要发现
- 中位总生存8.5个月,中位TTCP 8.1个月,中位CNS-PFS 5.0个月。
- 按脑转移数目分层,中位总生存:1个病灶11.0个月(95%CI 8.9-13.4),2-4个8.7个月(95%CI 7.7-10.4),5-10个8.0个月(95%CI 6.4-9.6),≥11个5.5个月(95%CI 4.3-7.6)。
- 12个月局部失败累积竞争风险估计7.0%(95%CI 4.9%-9.2%),12个月远处CNS失败41.6%(95%CI 37.6%-45.7%)。
- 软脑膜进展46/425例(10.8%),神经性死亡80/647例(12.4%)。
临床怎么用
- 对于小细胞肺癌脑转移患者,一线SRS可作为不联合WBRT的选择,但需权衡TTCP缩短的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although stereotactic radiosurgery (SRS) is preferred for limited brain metastases from most histologies, whole-brain radiotherapy (WBRT) has remained the standard of care for patients with small cell lung cancer. Data on SRS are limited. OBJECTIVE: To characterize and compare first-line SRS outcomes (without prior WBRT or prophylactic cranial irradiation) with those of first-line WBRT. DESIGN, SETTING, AND PARTICIPANTS: FIRE-SCLC (First-line Radiosurgery for Small-Cell Lung Cancer) was a multicenter cohort study that analyzed SRS outcomes from 28 centers and a single-arm trial and compared these data with outcomes from a first-line WBRT cohort. Data were collected from October 26, 2017, to August 15, 2019, and analyzed from August 16, 2019, to November 6, 2019. INTERVENTIONS: SRS and WBRT for small cell lung cancer brain metastases. MAIN OUTCOMES AND MEASURES: Overall survival, time to central nervous system progression (TTCP), and central nervous system (CNS) progression-free survival (PFS) after SRS were evaluated and compared with WBRT outcomes, with adjustment for performance status, number of brain metastases, synchronicity, age, sex, and treatment year in multivariable and propensity score-matched analyses. RESULTS: In total, 710 patients (median [interquartile range] age, 68.5 [62-74] years; 531 men [74.8%]) who received SRS between 1994 and 2018 were analyzed. The median overall survival was 8.5 months, the median TTCP was 8.1 months, and the median CNS PFS was 5.0 months. When stratified by the number of brain metastases treated, the median overall survival was 11.0 months (95% CI, 8.9-13.4) for 1 lesion, 8.7 months (95% CI, 7.7-10.4) for 2 to 4 lesions, 8.0 months (95% CI, 6.4-9.6) for 5 to 10 lesions, and 5.5 months (95% CI, 4.3-7.6) for 11 or more lesions. Competing risk estimates were 7.0% (95% CI, 4.9%-9.2%) for local failures at 12 months and 41.6% (95% CI, 37.6%-45.7%) for distant CNS failures at 12 months. Leptomeningeal progression (46 of 425 patients [10.8%] with available data) and neurological mortality (80 of 647 patients [12.4%] with available data) were uncommon. On propensity score-matched analyses comparing SRS with WBRT, WBRT was associated with improved TTCP (hazard ratio, 0.38; 95% CI, 0.26-0.55; P < .001), without an improvement in overall survival (median, 6.5 months [95% CI, 5.5-8.0] for SRS vs 5.2 months [95% CI, 4.4-6.7] for WBRT; P = .003) or CNS PFS (median, 4.0 months for SRS vs 3.8 months for WBRT; P = .79). Multivariable analyses comparing SRS and WBRT, including subset analyses controlling for extracranial metastases and extracranial disease control status, demonstrated similar results. CONCLUSIONS AND RELEVANCE: Results of this study suggest that the primary trade-offs associated with SRS without WBRT, including a shorter TTCP without a decrease in overall survival, are similar to those observed in settings in which SRS is already established.
引用
- Rusthoven CG, Yamamoto M, Bernhardt D, et al. Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases: The FIRE-SCLC Cohort Study. JAMA Oncol. 2020. PMID: 32496550. doi:10.1001/jamaoncol.2020.1271
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。